What does TRANSMED do?

TRANSMED is a shoe shop in Boutersem. Private Limited, started on 2 August 1995, 1 establishment.

What is the address of TRANSMED?

The registered office of TRANSMED is located at Pastoriestraat 76, 3370 Boutersem.

Is TRANSMED still active?

Yes. According to the CBE (29 October 2026) TRANSMED is active, legal situation “Normale toestand”, started on 2 August 1995.

Is TRANSMED registered on Peppol?

Yes, TRANSMED is registered on the Peppol network with ID 0208:0455685313.

What is the enterprise number of TRANSMED?

The enterprise number of TRANSMED is BE0455685313.

When was TRANSMED founded?

TRANSMED was founded on 2 August 1995.

Who are the directors of TRANSMED?

According to the 2025 annual accounts, the directors of TRANSMED are: Nathalie Homblé.

Is TRANSMED a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 2 August 1995; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did TRANSMED make in 2025?

TRANSMED recorded a loss after taxes of € 17,090 in financial year 2025.

What is the revenue of TRANSMED?

As a small company, TRANSMED is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 2,901.

TRANSMED (Private Limited) - Boutersem - BE0455685313

Dossier TRANSMED, printed on 29 October 2026 from databakkes.be/en/0455685313/transmed. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 3 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

TRANSMED from Boutersem, company number BE0455685313, closed financial year 2025 with a result of € -17,090 after tax. For that financial year TRANSMED recorded a gross margin of € 2,901 and equity of € -168,669. Compared with financial year 2024, the result moved from € -4,048 to € -17,090. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on January 30, 2026.

What it is worth Caution

€ -168,669

▼ € 17,090 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -17,090

▼ 322 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 2,728

▼ 1% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -187,261.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Wage cost

€ 17,182

▼ 10% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 1,307

▼ 36% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 18,769

▲ 2% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 10,138

▲ 126% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 33,127 Gross margin 2022: € 33,127 First fiscal year in the series	€ 34,212 Gross margin 2023: € 34,212 ▲ 3% vs 2022 (€ 33,127) Favourable step	€ 20,205 Gross margin 2024: € 20,205 ▼ 41% vs 2023 (€ 34,212) Unfavourable step	€ 2,901 Gross margin 2025: € 2,901 ▼ 86% vs 2024 (€ 20,205) Unfavourable step	▼ 86%
Profit after taxes	€ 11,465 Profit after taxes 2022: € 11,465 First fiscal year in the series	€ 10,097 Profit after taxes 2023: € 10,097 ▼ 12% vs 2022 (€ 11,465) Unfavourable step	€ -4,048 Profit after taxes 2024: € -4,048 ▼ € 14,145 vs 2023 (€ 10,097) Unfavourable step	€ -17,090 Profit after taxes 2025: € -17,090 ▼ € 13,042 vs 2024 (€ -4,048) Unfavourable step	▼ € 13,042
Equity	€ -157,628 Equity 2022: € -157,628 First fiscal year in the series	€ -147,531 Equity 2023: € -147,531 ▲ € 10,097 vs 2022 (€ -157,628) Favourable step	€ -151,579 Equity 2024: € -151,579 ▼ € 4,048 vs 2023 (€ -147,531) Unfavourable step	€ -168,669 Equity 2025: € -168,669 ▼ € 17,090 vs 2024 (€ -151,579) Unfavourable step	▼ € 17,090
Total debts	€ 232,026 Total debts 2022: € 232,026 First fiscal year in the series	€ 216,161 Total debts 2023: € 216,161 ▼ 7% vs 2022 (€ 232,026) Favourable step	€ 204,112 Total debts 2024: € 204,112 ▼ 6% vs 2023 (€ 216,161) Favourable step	€ 212,707 Total debts 2025: € 212,707 ▲ 4% vs 2024 (€ 204,112) Unfavourable step	▲ 4%
Cash	€ 14,927 Cash 2022: € 14,927 First fiscal year in the series	€ 11,580 Cash 2023: € 11,580 ▼ 22% vs 2022 (€ 14,927) Unfavourable step	€ 2,751 Cash 2024: € 2,751 ▼ 76% vs 2023 (€ 11,580) Unfavourable step	€ 2,728 Cash 2025: € 2,728 ▼ 1% vs 2024 (€ 2,751) Unfavourable step	▼ 1%
Retained profit	€ -176,220 Retained profit 2022: € -176,220 First fiscal year in the series	€ -166,123 Retained profit 2023: € -166,123 ▲ € 10,097 vs 2022 (€ -176,220) Favourable step	€ -170,171 Retained profit 2024: € -170,171 ▼ € 4,048 vs 2023 (€ -166,123) Unfavourable step	€ -187,261 Retained profit 2025: € -187,261 ▼ € 17,090 vs 2024 (€ -170,171) Unfavourable step	▼ € 17,090
Balance sheet total	€ 74,398 Balance sheet total 2022: € 74,398 First fiscal year in the series	€ 68,630 Balance sheet total 2023: € 68,630 ▼ 8% vs 2022 (€ 74,398) Unchanged	€ 52,533 Balance sheet total 2024: € 52,533 ▼ 23% vs 2023 (€ 68,630) Unchanged	€ 44,039 Balance sheet total 2025: € 44,039 ▼ 16% vs 2024 (€ 52,533) Unchanged	▼ 16%

Key figures of TRANSMED, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to TRANSMED?

What happened at TRANSMED in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jan 30, 2026 New annual accounts for financial year 2025: loss of € 17,090. Source: NBB ↗
Aug 23, 1995 New establishment in Tienen. KBO
1995 Nathalie Homblé became a director. NBB
Aug 2, 1995 Start of the company according to the CBE. KBO

In short

From € 11,465 profit in 2022 to € 17,090 loss in 2025.

Paid € 1,155 in corporate taxes since 2022.

Best year ever: 2022, with € 11,465 profit.

Original PDFs at the National Bank ↗

Management

Nathalie Homblé

TRANSMED

Behind TRANSMED is Nathalie Homblé.

Directors

According to the 2025 annual accounts

Nathalie Homblé

Director

since 1995

Establishments

Establishment units

Physical locations of this company

Registered office

Pastoriestraat 76

3370 Boutersem

2.072.788.149

Leuvenselaan 467

3300 Tienen

Active since 23 August 1995

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

KARYON

€ 30,228 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0455.685.313

VAT number

BE 0455.685.313

Registered office

Pastoriestraat 76, 3370 Boutersem

Names & denominations

TRANSMED

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

2 August 1995

Peppol

Active · Active since 28 Nov 2025

Activities · NACE

Detailhandel in lederwaren en reisartikelen

Activiteiten van reclamebureaus

Publiciteitsagentschappen

Activiteiten van vertalers

Vertaaldiensten en tolken

Vertalers en tolken

View on CBE Public ↗ Annual accounts (NBB) ↗

TRANSMED

Warning lights

Financials

What happened to TRANSMED?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions